Mersedeh Bahr-Hosseini

Mersedeh Bahr-Hosseini

Auto-generated profile, based on publicly available information

Mersedeh Bahr-Hosseini

Department of Neurology (M.B.-H., J.L.S., D.S.L., L.K.S.), University of California, Los Angeles

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2023 in Stroke
Verified
Journal Article
Closed access
LWLawrence R. Wechsler
Lawrence R. Wechsler
OAOpeolu Adeoye
Opeolu Adeoye
FAFana Alemseged
Fana Alemseged
MBMersedeh Bahr-Hosseini
Mersedeh Bahr-Hosseini
EDEmir Deljkich
Emir Deljkich
OROn Behalf Of The Xiith Stroke Treatment Academic Industry Roundtable
On Behalf Of The Xiith Stroke Treatment Academic Industry Roundtable
The Stroke Treatment Academic Industry Roundtable XII included a workshop to discuss the most promising approaches to improve outcome from acute stroke. The workshop brought together representatives from academia, industry, and government representatives. The discussion examined approaches in 4 epochs: pre-reperfusion, reperfusion, post-reperfusion, and access to acute stroke interventions. The participants identified areas of priority for developing new and existing treatments and approaches to improve stroke outcomes. Although many advances in acute stroke therapy have been achieved, more work is necessary for reperfusion therapies to benefit the most possible patients. Prioritization of promising approaches should help guide the use of resources and investigator efforts.

1 July 2021 in Brain Stimulation
Verified
Journal Article
Open access
MBMersedeh Bahr-Hosseini
Mersedeh Bahr-Hosseini
MBMarom Bikson
Marom Bikson
The ubiquitous vascular response to transcranial electrical stimulation (tES) has been attributed to the secondary effect of neuronal activity forming the classic neurovascular coupling. However, the current density delivered transcranially concentrates in: A) the cerebrospinal fluid of subarachnoid space where cerebral vasculature resides after reaching the dural and pial surfaces and B) across the blood-brain-barrier after reaching the brain parenchyma. Therefore, it is anticipated that tES has a primary vascular influence. Focused review of studies that demonstrated the direct vascular response to electrical stimulation and studies demonstrating evidence for tES-induced vascular effect in coupled neurovascular systems. tES induces both primary and secondary vascular phenomena originating from four cellular elements; the first two mediating a primary vascular phenomenon mainly in the form of an immediate vasodilatory response and the latter two leading to secondary vascular effects and as parts of classic neurovascular coupling: 1) The perivascular nerves of more superficially located dural and pial arteries and medium-sized arterioles with multilayered smooth muscle cells; and 2) The endothelial lining of all vessels including microvasculature of blood-brain barrier; 3) Astrocytes; and 4) Neurons of neurovascular units. A primary vascular effect of tES is highly suggested based on various preclinical and clinical studies. We explain how the nature of vascular response can depend on vessel anatomy (size) and physiology and be controlled by stimulation waveform. Further studies are warranted to investigate the mechanisms underlying the vascular response and its contribution to neural activity in both healthy brain and pathological conditions - recognizing many brain diseases are associated with alteration of cerebral hemodynamics and decoupling of neurovascular units.

1 June 2023 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
MBMersedeh Bahr-Hosseini
Mersedeh Bahr-Hosseini
KNKambiz Nael
Kambiz Nael
GUGozde Unal
Gozde Unal
MIMarco Iacoboni
Marco Iacoboni
DLDavid S. Liebeskind
David S. Liebeskind
GAGilda Avila
Gilda Avila
Acute ischemic stroke (AIS) is a leading cause of death and disability across the US and around the world.1 Treatments for AIS are currently limited to reperfusion therapies: intravenous thrombolysis and endovascular thrombectomy. Many patients are not candidates for these therapies, and among those who receive them, the rate of excellent outcome remains low; only 20% to 30% are free from disability at 3 months poststroke.2-4 Therefore, there is a critical need to develop additional therapies for patients with AIS. In animal models of acute cerebral ischemia, cathodal transcranial direct current stimulation (C-tDCS) salvages ischemic tissue at risk of infarction, both through direct neuroprotection by inhibiting peri-infarct excitotoxic effects, inflammatory and apoptotic pathways,5 and through collateral perfusion enhancement by inducing vasodilation.6 C-tDCS has many advantages over existing therapies. Delivery of pharmacological agents to threatened tissues is constrained by the same blood flow diminution that is producing ischemia. In contrast, C-tDCS is a regionally directed therapy that instantly reaches maximum local concentration.7 In addition, via high-definition (HD) electrode montages, electrical field shape and coverage location can be tailored to the ischemic tissue at risk of infarction.

1 July 2023 in Stroke
Verified
Journal Article
Closed access
JSJeffrey L Saver
Jeffrey L Saver
EKElizabeth Klerman
Elizabeth Klerman
ABAlastair M. Buchan
Alastair M. Buchan
PCPatricia Calleja
Patricia Calleja
ILIgnacio Lizasoain
Ignacio Lizasoain
F(for the Leducq Consortium International pour la Recherche Circadienne sur l’AVC Effects in Stroke (CIRCA)
for the Leducq Consortium International pour la Recherche Circadienne sur l’AVC Effects in Stroke (CIRCA)
Increasing evidence indicates that circadian and diurnal rhythms robustly influence stroke onset, mechanism, progression, recovery, and response to therapy in human patients. Pioneering initial investigations yielded important insights but were often single-center series, used basic imaging approaches, and used conflicting definitions of key data elements, including what constitutes daytime versus nighttime. Contemporary methodologic advances in human neurovascular investigation have the potential to substantially increase understanding, including the use of large multicenter and national data registries, detailed clinical trial data sets, analysis guided by individual patient chronotype, and multimodal computed tomographic and magnetic resonance imaging. To fully harness the power of these approaches to enhance pathophysiologic knowledge, an important foundational step is to develop standardized definitions and coding guides for data collection, permitting rapid aggregation of data acquired in different studies, and ensuring a common framework for analysis. To meet this need, the Leducq Consortium International pour la Recherche Circadienne sur l’AVC (CIRCA) convened a Consensus Statement Working Group of leading international researchers in cerebrovascular and circadian/diurnal biology. Using an iterative, mixed-methods process, the working group developed 79 data standards, including 48 common data elements (23 new and 25 modified/unmodified from existing common data elements), 14 intervals for time-anchored analyses of different granularity, and 7 formal, validated scales. This portfolio of standardized data structures is now available to assist researchers in the design, implementation, aggregation, and interpretation of clinical, imaging, and population research related to the influence of human circadian/diurnal biology upon ischemic and hemorrhagic stroke.

1 October 2019 in Stroke
Verified
Journal Article
Closed access
PDF file
MHMersedeh Bahr Hosseini
Mersedeh Bahr Hosseini
JHJesse Hou
Jesse Hou
MBMarom Bikson
Marom Bikson
MIMarco Iacoboni
Marco Iacoboni
JGJeffrey Gornbein
Jeffrey Gornbein
JSJeffrey L. Saver
Jeffrey L. Saver
Background and Purpose—: Brain electrical stimulation, widely studied to facilitate recovery from stroke, has also been reported to confer direct neuroprotection in preclinical models of acute cerebral ischemia. Systematic review of controlled preclinical acute cerebral ischemia studies would aid in planning for initial human clinical trials. Methods—: A systematic Medline search identified controlled, preclinical studies of central nervous system electrical stimulation in acute cerebral ischemia. Studies were categorized among 6 stimulation strategies. Three strategies applied different stimulation types to tissues within the ischemic zone (cathodal hemispheric stimulation [CHS], anodal hemispheric stimulation, and pulsed hemispheric stimulation), and 3 strategies applied deep brain stimulation to different neuronal targets remote from the ischemic zone (fastigial nucleus stimulation, subthalamic vasodilator area stimulation, and dorsal periaqueductal gray stimulation). Random-effects meta-analysis assessed electrical stimulation modification of final infarct volume. Study-level risk of bias and intervention-level readiness-for-translation were assessed using formal rating scales. Results—: Systematic search identified 28 experiments in 21 studies, including a total of 350 animals, of electrical stimulation in preclinical acute cerebral ischemia. Overall, in animals undergoing electrical stimulation, final infarct volumes were reduced by 37% (95% CI, 34%–40%; P <0.001), compared with control. There was evidence of heterogeneity of efficacy among stimulation strategies ( I 2 =93.1%, P heterogeneity <0.001). Among the within-ischemic zone stimulation strategies, only CHS significantly reduced the infarct volume (27 %; 95% CI, 22%–33%; P <0.001); among the remote-from ischemic zone approaches, all (fastigial nucleus stimulation, subthalamic vasodilator area stimulation, and dorsal periaqueductal gray stimulation) reduced infarct volumes by approximately half. On formal rating scales, CHS studies had the lowest risk of bias, and CHS had the highest overall quality of intervention-level evidence supporting readiness to proceed to clinical testing. Conclusions—: Electrical stimulation reduces final infarct volume across preclinical studies. CHS shows the most robust evidence and is potentially appropriate for progression to early-stage human clinical trial testing as a promising neuroprotective intervention.

23 April 2020 in International Journal of Stroke
Verified
Journal Article
Closed access
PDF file
MHMersedeh Bahr Hosseini
Mersedeh Bahr Hosseini
JSJeffrey L Saver
Jeffrey L Saver
Background: Sphenopalatine ganglion stimulation (SPG-Stim) for ischemic stroke, starting 8–24 h after onset and continuing through five days in a pooled analysis of two recent, randomized, sham-controlled trials, improved outcome of acute ischemic stroke patients with confirmed cortical involvement. As a neuromodulatory therapy, SPG-Stim differs substantially from existing pharmacologic (lytic and antiplatelets) and device (endovascular thrombectomy) acute ischemic stroke treatments. Aim: Focused review of SPG anatomy, physiology, and neurovascular and neurobiologic mechanisms of action mediating benefit of SPG-Stim in acute ischemic stroke. Summary of review: Located posterior to the maxillary sinus, the SPG is the main source of parasympathetic innervation to the anterior circulation. Preclinical and human studies delineate four distinct mechanisms of action by which the SPG-Stim may confer benefit in acute ischemic stroke: (1) collateral vasodilation and enhanced cerebral blood flow, mediated by release of neurotransmitters with vasodilatory effects, nitric oxide, and acetylcholine, (2) stimulation frequency- and intensity-dependent stabilization of the blood–brain barrier, reducing edema (3) direct acute neuroprotection from activation of the central cholinergic system with resulting anti-inflammatory, anti-apoptotic, and anti-excitatory effects; and (4) neuroplasticity enhancement from enhanced central cholinergic and adrenergic neuromodulation of cortical networks and nitrous oxide release stimulating neurogenesis. Conclusion: The benefit of SPG-Stim in acute ischemic stroke is likely conferred not only by potent collateral augmentation, but also blood–barrier stabilization, direct neuroprotection, and neuroplasticity enhancement. Further studies clarifying the relative contribution of these mechanisms and the stimulation protocols that maximize each may help optimize SPG-Stim as a therapy for acute ischemic stroke.